tiprankstipranks
Trending News
More News >
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Advertisement

Lisata Therapeutics (LSTA) AI Stock Analysis

Compare
1,048 Followers

Top Page

LSTA

Lisata Therapeutics

(NASDAQ:LSTA)

Rating:43Neutral
Price Target:
Lisata Therapeutics is navigating through financial difficulties with persistent losses and negative cash flows. The stock's technical indicators and valuation reflect a challenging financial position. However, recent advancements in clinical trials and regulatory achievements offer potential upside, albeit with high risk.
Positive Factors
Clinical Development
Lisata has reached agreement with the FDA on key elements of an acceptable Phase 3 protocol, marking a significant step forward in their clinical development process.
Earnings
Lisata announced 2Q25 financial results, posting EPS of ($0.54) which exceeded both the company's and consensus estimates.
Strategic Collaboration
Expanded strategic collaboration with GATC Health is anticipated to de-risk and accelerate drug development, potentially leading to new revenue streams.
Negative Factors
Competitive Landscape
Despite promising data, competition in the pancreatic cancer treatment space remains intense, which could impact market share and future growth.
Financial Health
Lisata ended the quarter with approximately $22 million in cash, which may raise concerns about long-term financial sustainability beyond 4Q26 without new funding or revenue.

Lisata Therapeutics (LSTA) vs. SPDR S&P 500 ETF (SPY)

Lisata Therapeutics Business Overview & Revenue Model

Company DescriptionLisata Therapeutics (LSTA) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for the treatment of cardiovascular diseases and other critical health conditions. The company operates primarily in the biotechnology and pharmaceuticals sectors, striving to address unmet medical needs through its proprietary therapeutic platforms and drug candidates.
How the Company Makes MoneyLisata Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company may earn money via partnerships with larger pharmaceutical companies, licensing agreements, and potential sales of its approved therapies. Additionally, Lisata could receive milestone payments and royalties based on the successful development and commercialization of its products. However, as a clinical-stage company, Lisata's revenue generation is typically dependent on the progression of its drug candidates through clinical trials and eventual regulatory approvals.

Lisata Therapeutics Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with significant achievements in strategic partnerships and promising clinical results for certepetide. Financial management appears strong with reduced costs and an extended cash runway. However, the company's minimal current revenue and dependency on future funding are concerning. Despite these challenges, the highlights slightly outweigh the lowlights, suggesting cautious optimism.
Q2-2025 Updates
Positive Updates
Strategic Alliances and Collaborations
Lisata signed a research agreement with Catalent and formed a strategic alliance with GATC Health, enhancing their development capabilities and exploring new drug development candidates.
Encouraging Preliminary Trial Results
Preliminary results from ASCEND and iLSTA trials showed promising data for certepetide, indicating positive signals in progression-free survival and objective response rates.
Expense Management and Financial Position
Operating expenses decreased by 10.6% from the previous year, with a reduction in research and development expenses by 13.4%, demonstrating effective cost management.
Patent Extension
A new composition of matter patent for certepetide was issued, extending protection until March 2040, strengthening the company's intellectual property position.
Cash Runway Extension
With $22 million in cash and equivalents, the company expects to support current operations into the fourth quarter of 2026.
Negative Updates
Minimal Revenue Generation
Revenue was only $70,000 for the quarter, stemming from an upfront license fee, indicating limited income generation from operations.
Dependency on Future Funding
Continued operations and future clinical trials depend on securing additional funding, highlighting financial vulnerability.
Company Guidance
During the Lisata Therapeutics Second Quarter 2025 Financial Results and Business Update Conference Call, key financial metrics revealed that the company generated $70,000 in revenue for the quarter ending June 30, 2025, from an upfront license fee with Catalent, compared to no revenue in the same period in 2024. Operating expenses decreased by 10.6% from $5.5 million in 2024 to $4.9 million in 2025, with research and development expenses reducing by 13.4% to $2.3 million, and general and administrative expenses declining by 8.1% to $2.7 million. The net loss was $4.7 million, down from $5 million in 2024. Lisata reported having cash, cash equivalents, and marketable securities totaling $22 million as of June 30, 2025, projecting that available funds would support operations into the fourth quarter of 2026. These results underscore Lisata's continued focus on prudent capital management while advancing its development programs.

Lisata Therapeutics Financial Statement Overview

Summary
Lisata Therapeutics faces significant financial challenges with ongoing losses and negative cash flows. Despite a strong equity position and no debt, the lack of revenue consistency and high operational costs are critical concerns.
Income Statement
30
Negative
Lisata Therapeutics has faced significant challenges with revenue and profitability. The company reported a substantial net loss of $19,985,000 in the most recent year, despite a modest revenue of $1,000,000. Gross profit margin is quite high at 100% due to minimal cost of goods sold, but this is overshadowed by negative EBIT and EBITDA margins, indicating operational inefficiencies. The revenue growth rate is not applicable, given the absence of revenue in the prior year, which highlights volatility in revenue generation.
Balance Sheet
45
Neutral
The company's balance sheet shows moderate strength with a high equity ratio of 84.5%, and zero total debt suggesting financial prudence in leveraging. However, the return on equity is negative due to ongoing losses, which is a concern. Cash reserves have declined over the years, reflecting the company's cash burn rate amid its losses.
Cash Flow
40
Negative
The cash flow statement reveals a negative free cash flow of $19,356,000, indicating the company is not generating enough cash to cover its expenditures. The operating cash flow to net income ratio is positive, yet the absolute cash flow figures remain negative. The absence of capital expenditures suggests limited investment in growth initiatives.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.07M1.00M0.00121.37M0.000.00
Gross Profit942.00K1.00M-189.00K63.77M-55.00K-63.00K
EBITDA-20.12M-22.23M-25.52M-56.63M-29.00M-19.08M
Net Income-18.92M-19.98M-20.84M-54.23M-27.47M-8.15M
Balance Sheet
Total Assets25.16M35.00M54.69M73.03M97.01M36.00M
Cash, Cash Equivalents and Short-Term Investments21.97M31.25M50.53M69.23M94.97M34.57M
Total Debt47.00K137.00K305.00K485.00K714.00K624.00K
Total Liabilities4.38M5.68M6.80M6.71M5.01M3.76M
Stockholders Equity21.03M29.57M48.15M66.58M92.25M32.50M
Cash Flow
Free Cash Flow-16.40M-19.36M-20.03M-21.45M-22.30M-8.84M
Operating Cash Flow-16.40M-19.36M-20.03M-21.17M-22.25M-8.82M
Investing Cash Flow5.02M13.23M10.10M28.91M-54.90M-7.28M
Financing Cash Flow-55.00K-206.00K385.00K-224.00K85.28M18.58M

Lisata Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.17
Price Trends
50DMA
2.59
Negative
100DMA
2.52
Negative
200DMA
2.60
Negative
Market Momentum
MACD
-0.11
Positive
RSI
37.46
Neutral
STOCH
19.99
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSTA, the sentiment is Negative. The current price of 2.17 is below the 20-day moving average (MA) of 2.46, below the 50-day MA of 2.59, and below the 200-day MA of 2.60, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 37.46 is Neutral, neither overbought nor oversold. The STOCH value of 19.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LSTA.

Lisata Therapeutics Risk Analysis

Lisata Therapeutics disclosed 79 risk factors in its most recent earnings report. Lisata Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Lisata Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$89.54M-102.69%-3.20%12.24%
51
Neutral
$7.95B-0.40-41.62%2.21%22.29%-1.85%
43
Neutral
$19.00M-63.84%12.95%
38
Underperform
$22.28M-19.56%71.47%
35
Underperform
$31.50M-813.88%49.48%
33
Underperform
47.73%
$42.84M
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
LSTA
Lisata Therapeutics
2.17
-0.86
-28.38%
PMN
ProMIS Neurosciences
0.43
-0.82
-65.60%
IPA
ImmunoPrecise Antibodies
1.94
1.29
198.46%
BCAB
BioAtla
0.54
-1.28
-70.33%
ELEV
Elevation Oncology
0.36
-0.27
-42.86%
JUNS
Jupiter Neurosciences, Inc.
1.23
-4.31
-77.80%

Lisata Therapeutics Corporate Events

Business Operations and StrategyFinancial Disclosures
Lisata Therapeutics Reports 2024 Financial Results and Updates
Positive
Feb 27, 2025

On February 27, 2025, Lisata Therapeutics reported its financial results for the fiscal year ending December 31, 2024, and provided a business update. The company highlighted promising preliminary data from its Phase 2b ASCEND trial for pancreatic cancer and announced the completion of enrollment in Qilu’s Phase 2 trial for certepetide. Lisata is advancing its development portfolio with multiple milestones expected over the next year, supported by a cash runway extending into the second quarter of 2026. The company is conducting several clinical trials globally, focusing on the efficacy of certepetide in combination with standard-of-care treatments for various cancers, including pancreatic, cholangiocarcinoma, and glioblastoma.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 20, 2025